Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29817086 | 1.00 | TTR (0.43) | TTRALBMEN1KMT2ACA12 | |
| SCHEMBL3608019 | 0.82 | KCNH2 (0.45) | TTRALBMEN1KMT2ACA12 | |
| SCHEMBL509092 | 0.82 | CA12 (0.52) | TTRALBMEN1KMT2ACA12 | |
| SCHEMBL214163 | 0.82 | CA12 (0.52) | TTRALBMEN1KMT2ACA12 | |
| SCHEMBL9264989 | 0.82 | CA12 (0.52) | TTRALBMEN1KMT2ACA12 | |
| SCHEMBL5852713 | 0.82 | VCAM1 (0.43) | TTRALBMEN1KMT2AGRM5 | |
| SCHEMBL633226 | 0.82 | TSHR (0.50) | TTRALBMEN1KMT2AGRM5 | |
| SCHEMBL13140964 | 0.78 | KCNH2 (0.42) | TTRALBMEN1KMT2ACA12 | |
| SCHEMBL7034739 | 0.76 | HCAR1 (0.40) | HCAR1TSHR | |
| SCHEMBL16954874 | 0.76 | HCAR1 (0.40) | HCAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110885291-B | Synthetic method of 3-chloro-5- (difluoromethoxy) benzylamine | 阿里生物新材料（常州）有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-109212110-B | Gas chromatography-mass spectrometry combined method for measuring three trace monohalogenated hydroxyl benzonitrile in river water | 丁立平 | 2021-05-11 | — | — | CN | claimed |
| CN-110885291-A | Synthetic method of 3-chloro-5- (difluoromethoxy) benzylamine | 阿里生物新材料（常州）有限公司 | 2020-03-17 | — | — | CN | claimed |
| CN-122036680-A | Anti-fibrotic pyridones | 英特穆恩公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-28 | — | — | US | disclosed |
| US-20250340508-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391642-B2 | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-115485262-B | Hypoxia inducible factor-2 (alpha) inhibitors and their use in the treatment of disease | 霖康疗法公司 | 2025-04-04 | — | — | CN | disclosed |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | MERCK SHARP & DOHME LLC (US) | 2025-03-25 | — | — | US | disclosed |
| CN-114026081-B | Pyridone derivatives as selective cytotoxic agents against HIV-infected cells | 默沙东有限责任公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12171741-B2 | 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
| WO-2004085406-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| CN-1514828-A | Pyrazole derivatives for treating HIV | — | 2004-07-21 | — | — | CN | disclosed |
| US-20040133002-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004031178-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004029051-A1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | CTRL, PTMS, DDT | TTR 1446/4885ALB 2123/4885MEN1 4381/4885 |
| US-20250340508-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | HIF1AN, HIF1A, HYOU1 | TTR 4555/4885ALB 3824/4885MEN1 4700/4885 |
| US-12391642-B2 | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | HIF1AN, HIF1A, HYOU1 | TTR 4555/4885ALB 3824/4885MEN1 4700/4885 |
| US-20040133002-A1 | Pyrazole derivatives | REV1, RRS1, CYP2F1 | TTR 2118/4885ALB 3611/4885MEN1 4791/4885 |
| US-12171741-B2 | 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors | HIF1AN, HIF1A, EGLN2 | TTR 3179/4885ALB 3798/4885MEN1 4771/4885 |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | TTR 1561/4885ALB 4644/4885MEN1 4616/4885 |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | TYMP, PNP, CD4 | TTR 2015/4885ALB 4437/4885MEN1 4689/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | TTR 1407/4885ALB 3317/4885MEN1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.